Format

Send to

Choose Destination
Leuk Lymphoma. 2018 Mar;59(3):542-561. doi: 10.1080/10428194.2017.1337115. Epub 2017 Jun 13.

Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Author information

1
a Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
2
b UCD School of Medicine, College of Health and Agricultural Science and UCD Conway Institute of Biomolecular and Biomedical Research , University College Dublin , Dublin , Ireland.
3
c Department of Hematology , West China Hospital, Sichuan University , Chengdu , China.
4
d Department of Haematology , Mater Misericordiae University Hospital , Dublin , Ireland.

Abstract

Multiple myeloma (MM) is among the most compelling examples of cancer in which research has markedly improved the length and quality of lives of those afflicted. Research efforts have led to 18 newly approved treatments over the last 12 years, including seven in 2015. However, despite significant improvement in overall survival, MM remains incurable as most patients inevitably, yet unpredictably, develop refractory disease. Recent advances in high-throughput 'omics' techniques afford us an unprecedented opportunity to (1) understand drug resistance at the genomic, transcriptomic, and proteomic level; (2) discover novel diagnostic, prognostic, and therapeutic biomarkers; (3) develop novel therapeutic targets and rational drug combinations; and (4) optimize risk-adapted strategies to circumvent drug resistance, thus bringing us closer to a cure for MM. In this review, we provide an overview of 'omics' technologies in MM biomarker and drug discovery, highlighting recent insights into MM drug resistance gleaned from the use of 'omics' techniques. Moving from the bench to bedside, we also highlight future trends in MM, with a focus on the potential use of 'omics' technologies as diagnostic, prognostic, or response/relapse monitoring tools to guide therapeutic decisions anchored upon highly individualized, targeted, durable, and rationally informed combination therapies with curative potential.

KEYWORDS:

Multiple myeloma; bench to bedside; drug resistance; genomics; immunomics; immunotherapy; metabolomics; omics; proteomics; transcriptomics; translational medicine

PMID:
28610537
PMCID:
PMC6152877
DOI:
10.1080/10428194.2017.1337115
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center